A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Inclusion Criteria

• 55 years of age or older with histologically-confirmed unresectable, locally advanced, or metastatic solid tumor with AXIN1 or APC mutation. If a participant has colorectal cancer, then they must be RAS / RAF wild type to enroll into the APC mutant cohort
• Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment, or in the opinion of the Investigator have been considered ineligible for standard therapy
• Measurable disease at baseline per RECIST 1.1 criteria
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion Criteria

• Received treatment with another mitogen-activated protein kinase (MEK) inhibitor within two months of first dose of REC-4881
• Left ventricular ejection fraction (LVEF) <50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan